Dataset Information


HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.

ABSTRACT: BACKGROUND:With the phase-out of stavudine (d4T), change to first-line regimens with zidovudine (AZT) or tenofovir (TDF) in resource-limited settings (RLS) might increase risks of cross-resistance to nucleos(t) ide reverse transcriptase inhibitors (NRTI). This would restrict the scope of switching to the World Health Organisation (WHO)-recommended standard second-line combinations (SLC) without HIV drug resistance (HIVDR)-testing in routine clinical practice. METHODS:An observational study was conducted among 101 Cameroonian patients (55.4% male, median [IQR] age 34 [10-41] years) failing first-line antiretroviral therapy (ART) in 2016, and stratified into three groups according to NRTIs exposure: exposure to both thymidine analogues AZT "and" D4T (group-A, n =?55); exposure to both TDF and AZT "or" D4T (group-B, n =?22); exposure solely to D4T (group-C, n =?24). Protease-reverse transcriptase HIVDR was interpreted using the HIVdb penalty scores (?60: high-resistance; 20-59: intermediate-resistance;

PROVIDER: S-EPMC6419466 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC4320083 | BioStudies
| S-EPMC7430722 | BioStudies
2018-01-01 | S-EPMC6320000 | BioStudies
| S-EPMC3694021 | BioStudies
| S-EPMC3353948 | BioStudies
2014-01-01 | S-EPMC4224833 | BioStudies
| S-EPMC5402603 | BioStudies
| S-EPMC5825249 | BioStudies
| S-EPMC4136047 | BioStudies
| S-EPMC5405160 | BioStudies